[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"smokers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:smokers":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,80,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100636177","periodontal-health-among-cigarette-electronic-cigarettes-and-narghile-smokers-100636177",false,"NCT07562295","Periodontal Health Among Cigarette, Electronic Cigarettes, and Narghile Smokers","Evaluation of Periodontal Health Among Cigarette, Electronic Cigarettes, and Narghile Smokers Among a Sample of Alhawsh Private University Students","Inclusion Criteria:\n\n* Cigarette smokers: Individuals who have smoked five or more cigarettes per day for at least one year.\n* E-cigarette smokers: Individuals who have smoked e-cigarettes one or more times per day for at least one year.\n* narghile smokers: Individuals who have used a hookah one or more times per day for at least one year.\n\nExclusion Criteria:\n\n* Non-smokers\n* Ages older than 25 years\n* Dual smokers: Individuals who smoke two or more types of tobacco.\n* Individuals with systemic diseases, such as diabetes, heart disease, liver problems, and kidney disease\n* Individuals who reported using antibiotics, steroids, or NSAIDs within the past month\n* Individuals who have received periodontal treatment at least six months ago","ALL","18 Years","25 Years",{"count":20,"type":21},90,"ESTIMATED","OBSERVATIONAL","This study compares the different effects of traditional cigarettes, e-cigarettes, and narghile on periodontal health among a sample of Al-Hawash Private University students. The main question it aims to answer is: Are there statistically significant differences in periodontal parameters among different types of smokers?",[25,26],"Smokers","Periodontal Status",[28,29,30,31,32],"Smoking","Cigarettes","Periodontal Health","Electronic Cigarettes","Narghile Smokers","RECRUITING","2026-04-25",{"date":36,"type":37},"2026-05-01","ACTUAL",{"date":39,"type":37},"2025-06-01",{"date":41,"type":21},"2026-08",{"name":43,"class":44},"Al-Hawash Private University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":45},"100614681","evaluation-of-the-efficacy-of-subgingival-application-of-lovastatin-gel-as-an-adjunct-to-non-surgical-treatment-of-periodontitis-in-generally-healthy-smokers-and-non-smokers-patients-in-central-europe-100614681","NCT07282756","Evaluation Of The Efficacy Of Subgingival Application Of Lovastatin Gel As An Adjunct To Non-Surgical Treatment Of Periodontitis In Generally Healthy Smokers And Non-Smokers Patients in Central Europe.","Assessment of Changes in Clinical and Radiological Parameters in Gingival Pockets After Subgingival Application of Lovastatin Gel in Combination With SRP Procedure Compared to SRP and Placebo Gel Application in the Treatment of Periodontal Disease in Generally Healthy Non-smokers and Smokers From Central Europe: a Split-mouth Randomized Controlled Trial.","RCT","Inclusion Criteria:\n\n* generally healthy patients\n* diagnosed periodontal disease (at least one pair of non-adjacent sites with PD≥5 mm or CAL ≥4 mm and vertical bone loss ≥ 3 mm)\n* no history of periodontal disease treatment\n* no history of antibiotic use in the past 6 months\n* an eligible tooth must be alive, with no history of endodontic treatment\n* non-smoking (group I) or active smokers (group 2)\n\nExclusion Criteria:\n\n* Statin allergy\n* receiving systemic statin therapy,\n* alcoholics\n* immunocompromised patients\n* pregnant or breastfeeding women.","59 Years",{"count":56,"type":21},44,"INTERVENTIONAL",[59],"NA","The aim of the study is to evaluate how a gel (1.2% lovastatin) applied under the gum improves the results of classic periodontal treatment (SRP-scaling, root planing).\n\nThe study involves two groups of adults diagnosed with periodontitis: the first group consists of generally healthy individuals who do not smoke tobacco. The second group consists of generally healthy individuals who have been smoking for at least 5 years. Before the study begins, each participant will undergo gum health measurements. Changes in these parameters will be monitored throughout the study. Two teeth will be selected for each participant:\n\n* a gel containing the medication will be applied under the gum of one tooth\n* a gel that looks similar to the medication but does not contain any medicinal substance will be applied under the gum of the second tooth.\n\nBefore applying the gel, each participant will undergo subgingival cleaning (SRP) to remove any debris that may prevent the medicine from working.\n\nThe study will last six months.\n\nExpected results:\n\n* all participants will experience an improvement in the condition of their gums after treatment\n* the effect of treatment will be better in non-smokers than in smokers\n* the treatment outcome will be better in the area where the medicated gel was applied compared to areas where the gel without medicinal substances was applied.",[62,63,64,25],"Periodontal Diseases","Periodontitis","Periodontal Disease",[66,67,68,69,70],"periodontitis","statins","lovastatin","smoking","periodontal disease","2026-02-18",{"date":73,"type":37},"2026-02-20",{"date":75,"type":37},"2025-07-11",{"date":77,"type":21},"2026-12",{"name":79,"class":44},"Medical University of Silesia",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":57,"phases":91,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":45},"100597475","phase-1-a-study-of-exercise-and-pharmacologic-intervention-on-systemic-inflammation-100597475","NCT07058974","A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation","A Phase 1b, Multi-cohort Clinical Trial Assessing Safety and Feasibility of Exercise and Spermidine Administered in Conjunction With Lamivudine (RTi) or Rapamycin (mTORi) to Assess Impact on Dynamic Changes of Inflammation and Aging","Inclusion Criteria:\n\n* Patients 65-80 years old\n* Current or former smokers\n* BMI 25-32\n* No cancer requiring active therapy within the last 2 years\n* No autoimmune disease requiring disease modifying agents\n* No patients with CKD stage 3\u002F4 or ESRD\n* No class 3 or 4 heart failure\n\nExclusion Criteria:\n\n* Patients may not have cancer requiring active therapy within the last 2 years\n* Patients may not have autoimmune disease requiring disease modifying agents\n* Patients may not be receiving immune modifying biologic therapies\n* Patients may not have chronic kidney disease stage 3\u002F4 or end stage renal disease\n* Patients may not have a known history of metabolic dysfunction-associated steatohepatitis\n* Patients may not have a known chronic viral infection such as HIV or active Hepatitis B or C, or a known history of genital HSV. Patients who have spontaneously or through treatment cleared hepatitis B or C are candidates for the trial. If Hepatitis B core ab is positive must document a negative PCR.\n* Patients may not have class 3 or 4 heart failure, or have experienced a myocardial infarction or cerebrovascular event in the past 6 months\n* Patients may not have uncontrolled diabetes mellitus\n* Patients may not have a history of clinically significant interstitial lung disease (ILD).\n* Patients may not have clinically significant active wound healing due to recent injury or surgery\n* Patients may not have signs or symptoms of clinically significant acute infectious illness on screening laboratory testing or physical examination.\n* Patients may not have evidence of active or latent tuberculosis\n* Patients may not have nephrotic range proteinuria on screening labs\n* Patients may not have received a live virus within one month of study initiation.\n* Patients cannot have uncontrolled hypertension (persistent systolic \\>160; diastolic \\>100)\n* Patients with an inherited primary immunodeficiency\n* Patients may not have a history of, or current evidence of, clinically significant chronic liver disease\n* Patients may not be receiving any chronic immunosuppressive therapy.\n* Patients may not be receiving medications that could increase rapamycin blood concentrations, such as strong inhibitors and inducers of CYP3A4 and\u002For P-gp (ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, or clarithromycin; rifampin or rifabutin), bromocriptine, cimetidine, cisapride, clotrimazole, danazol, diltiazem, fluconazole, protease inhibitors, metoclopramide, nicardipine, troleandomycin, verapamil. Furthermore, these medications may not be used during the study if patient is assigned to the rapamycin cohort.\n* Patients may not be receiving medications that could decrease rapamycin blood concentrations, such as: carbamazepine, phenobarbital, phenytoin, rifapentine, St. John's Wort. Furthermore, these medications may not be used during the study if patient is assigned to the rapamycin cohort.\n* Patients may not be receiving medications known to cause angioedema with concomitant use of rapamycin, such as angiotensin-converting enzyme (ACE) inhibitors. Furthermore, these medications may not be used during the study if patient is assigned to the rapamycin cohort.","65 Years","80 Years",{"count":90,"type":21},22,[92],"PHASE1","This is a study assessing the feasibility of performing an anti-aging intervention which is a combination of an exercise regimen, spermidine supplementation, and either rapamycin or lamivudine.",[25,95],"Former Smokers","2025-09-21",{"date":98,"type":37},"2025-09-25",{"date":100,"type":37},"2025-08-25",{"date":102,"type":21},"2026-07-01",{"name":104,"class":44},"Icahn School of Medicine at Mount Sinai",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":112,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":57,"phases":115,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":129,"locationsCount":45},"100381912","incident-chronic-obstructive-pulmonary-disease-cohort-study-iconic-100381912","NCT04252781","Incident Chronic Obstructive pulmoNary dIsease Cohort Study (ICONIC)","ICONIC","Inclusion Criteria:\n\nInclusion criteria of smokers with spirometry (pre-inclusion)\n\n* Age\\> 35 years\n* Smoking \\> 20 PA\n* Active smoking (cessation \\\u003C 1 month)\n* Signature of consent to participate in Phase I of the study\n\nInclusion criteria for patients with incidental COPD\n\n* FEV1 \u002F FVC \\\u003C70% of the theoretical value and \u002F or \\\u003CLLN (Lower limit of normal)\n* Signature of consent to participate in Phase II of the study\n\nExclusion Criteria:\n\n* Known COPD\n* Cancer being treated\n* No affiliation to the social security or other social protection scheme\n* Pregnant or lactating woman\n* Patient deprived of liberty or under legal protection (under tutorship or curatorship","35 Years",{"count":114,"type":21},300,[59],"Chronic Obstructive Pulmonary Disease (COPD), , secondary to smoking, is a major public health issue with very high direct and indirect costs. The impact on the health system of undiagnosed patients, up to 70% of patients, is increasingly documented. However, systematic spirometry screening remains controversial among smokers in the absence of data to link the detection of new patients with improved management and clinical events and health goals. More generally, there is little data on the evolution of patients in real life once they have entered the care system.\n\nThe premise is that with systematic screening in general medicine, it is possible to identify the evolution of newly diagnosed COPD patients, to distinguish the different possible evolutions according to the initial phenotype and the management.",[25,118],"Chronic Obstructive Pulmonary Disease",[120,121,122],"Incident Chronic Obstructive Pulmonary Disease","comorbidities","trajectories","2025-01-07",{"date":125,"type":37},"2025-01-09",{"date":127,"type":37},"2020-08-20",{"date":73,"type":21},{"name":130,"class":44},"Assistance Publique - Hôpitaux de Paris"]